imatinib mesylate has been researched along with Diseases, Metabolic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, W; Chen, H; Chen, P; Chen, S; Deng, K; Fan, D; Gu, L; Guan, D; Guo, Z; He, X; Hu, A; Huang, B; Huang, K; Li, J; Li, L; Li, W; Li, Y; Li, Z; Lin, F; Liu, C; Liu, J; Lu, Y; Luo, H; Peng, J; Peng, M; Yan, L; Zhang, Y; Zhang, Z; Zhu, W; Zhu, Y | 1 |
| Catharino, RR; de Oliveira, AN; de Paula, EV; Delafiori, J; Dias-Audibert, FL; Lopes, ABP; Pagnano, KBB; Póvoa, VMO | 1 |
| Abdulkadyrov, K; Ayala, M; Babu, KG; Bendit, I; Bullorsky, E; Cortes, JE; de Oliveira, JSR; De Souza, CA; Fellague-Chebra, R; Huang, X; Khanna, S; le Coutre, PD; Liang, Z; Lopez, JL; Owugah, T; Sacha, T; Shah, S; Shen, ZX; Szczudlo, T | 1 |
| Etienne, G; Milpied, B; Nicolini, FE; Réa, D; Rigal-Huguet, F; Tulliez, M | 1 |
| Assouline, S; Benemacher, V; Franceschino, A; Gambacorti-Passerini, C; Tornaghi, L | 1 |
2 trial(s) available for imatinib mesylate and Diseases, Metabolic
| Article | Year |
|---|---|
Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Metabolic Diseases; Metabolome; Middle Aged; Non-Randomized Controlled Trials as Topic; Pioglitazone; Prognosis; Prospective Studies; Retrospective Studies; Withholding Treatment; Young Adult | 2021 |
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Asia; Biomarkers, Pharmacological; Bone Marrow; Comparative Effectiveness Research; Cytogenetic Analysis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Europe; Exanthema; Female; Fever; Follow-Up Studies; Headache; Hematologic Diseases; Humans; Imatinib Mesylate; Latin America; Leukemia, Myeloid, Chronic-Phase; Male; Metabolic Diseases; Middle Aged; Philadelphia Chromosome; Pyrimidines; Random Allocation; Treatment Failure | 2016 |
3 other study(ies) available for imatinib mesylate and Diseases, Metabolic
| Article | Year |
|---|---|
Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.
Topics: Angiotensin-Converting Enzyme 2; Animals; Cells, Cultured; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Down-Regulation; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Male; Metabolic Diseases; Methazolamide; Mice; Mice, Inbred C57BL; Mice, Obese; Mice, Transgenic; SARS-CoV-2; Vero Cells; Virus Internalization | 2022 |
[Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)].
Topics: Antineoplastic Agents; Benzamides; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; Erythropoietin; Fertility; Food-Drug Interactions; France; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metabolic Diseases; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins | 2010 |
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Creatine Kinase; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Phosphates; Piperazines; Pyrimidines; Retrospective Studies | 2008 |